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Objective: The superiority of blood cardioplegia in pediatric ardiac surgery 
has not previously been challenged in a controlled clinical trial. The 
purpose of this study was to compare antegrade cold blood versus cold 
crysta!loid cardioplegia in pediatric ardiac surgery. Methods: One hundred 
thirty-eight pediatric patients (mean age 32 months; 95% CL 24.2 to 39.8 
months; range 1 day to 15 years) were prospectively randomized to receive 
either cold blood (4:1 dilution, blood/Plegisol, potassium chloride 15 
mEq/L; n = 62) or cold crystalloid (Plegisol; n = 76) cardioplegic solution 
during a variety of operations for congenital heart disease. Multiple doses 
of cold (4 ° C) cardioplegic solution was administered antegradely in 
addition to topical cooling during ischemic arrest. Myocardial recovery and 
outcome measures were assessed by five clinical end points: (1) inotropic 
support, (2) echocardiographic assessment of ventricular function, (3) 
overall complication rate, (4) length of stay in the intensive care unit, and 
(5) 30-day survival. Multiple logistic regression and multivariate analysis 
of varianc e were used to investigate which of the following clinical deter- 
minants were contributory: (1) cardioplegia, (2) urgency of operation, (3) 
aortic crossclamp time, (4) age, and (5) cyanosis. Population data did not 
differ between the two cardioplegia groups (p > 0.05). Results: The most 
important clinical determinant of studied end points was the aortic 
crossclamp time (p < 0.05). The type of cardioplegic solution (blood vs 
crystalloid) was less important (p > 0.05). The only statistically significant 
difference between blood and crystalloid cardioplegia for the measured 
Clinical end points was the level of intraoperative inotropic support (p < 
0.05), although this did not correlate with any significant differences in 
measured ventricular function. Conclusion; Our results suggest no clear 
clinical advantage of antegrade cold blood cardioplegia over crystalloid 
cardiop!egia during hypothermic cardioplegic arrest in pediatric cardiac 
surgery, The aortic crossclamp time was the strongest predictor of mea- 
sured outcomes. (J Thorac Cardiovasc Surg 1997;114:1002-9) 
B lood cardioplegia has theoretic advantages over crystalloid cardioplegia, namely, improved oxy- 
gen delivery, onconicity, buffering capacity, and an- 
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tioxidant capability. Since its introduction in 1977, 
blood Cardioplegia has achieved a dominant role 
relative to crystalloid cardioplegia in adult cardiac 
surgery.i, 2The role and advantages of blood cardio- 
plegia in pediatric cardiac surgery are less well 
defined. Congenital heart surgeons are divided in 
regard to their use of blood and crystalloid car- 
dioplegic solutions. 3 No randomized clinical trial 
comparing these two cardioplegic agents has been 
reported in a pediatric scenario. We attempted to 
better define the role of blood cardioplegia for 
pediatric patients undergoing cardiac surgery by 
conducting a prospective randomized controlled 
clinical trial of antegrade cold blood versus ante- 
grade cold crystalloid cardioplegia. 
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TabLe I. Primary diagnoses and procedures performed for patients entered into the study (September 1994 
through December 1995) 
PHmary diagnosis Prirnaiy procedure n % of 138 
VSD VSD repair 59 42.8 
TOF* TOF repair 18 13.0 
Single ventricle* Fontan procedure 11 8.0 
AS AS repair/aortoplasty 8 5.8 
CAVC defect CAVC repair 8 5.8 
Conotruncal bnormality with VSD* Rastelli procedure 8 5.8 
TGA _+ VSD* Arterial switch _+ VSD 5 3.6 
TAPVC* TAPVC repair 5 3.6 
Complex RVOT/phlm. arterial reconstruction RVOT reconstruction 4 2.9 
Hypoplastic left heart syndrome* Norwood procedure 3 2.2 
DORV* DORV repair 2 1.4 
Aortic valvular insufficiency Ross procedure 2 1.4 
Mitral valvular insufficiency Mitral valve replacement 2 1.4 
Ebstein's anomaly with TGA* Damus procedure 1 0.7 
Subaortic stenosis Konno procedure 1 0.7 
Single ventricle with TGA* Bidirectional Glenn shunt 1 0.7 
VSD, Ventricular septal defect; TOF, tetralogy of Fallot; AS, aortic stenosis; CA VC, complete atrioventricular c nal; TG& transposition of the great arteries; 
TAPVC, total anomalous pulmonary venous connection; RVOT, right ventricular outflow tract; DORV, double-outlet right ventricle. 
*Cyanotic lesions (n - 54). 
Methods 
Patients. One hundred thirty-eight patients (75 male, 
63 female) undergoing a variety of congenital heart oper- 
ations requiring cardiopulmonary bypass and ischemic 
cardiac arrest were entered into the study from September 
1994 through December 1995. Isolated atrial septal de- 
fects (all variants) were prospectively excluded because of 
the anticipated brief ischemic times. Mean and median 
patient ages were 32.0 and 12.0 months, respectively (95% 
confidence limits [CL] 24.2 to 39.8 months; range 1 day to 
15 years). Thirty-seven patients (26.8%) were younger 
than 6 months of age. Table I shows the distribution of the 
primary diagnoses and operations performed. One hun- 
dred twenty cases (87%) were elective and 18 cases (13%) 
were urgent (operation required Within a 48-hour period). 
The mean and median ages for patients undergoing 
urgent operations were 2.4 and 0.5 months, respectively 
(95% CL 0.7 to 4.0 months; range 1 day to t0 months). 
Fifty-four operations (39%) were for cyanotic lesions. The 
mean and median ages for patients with cyanotic lesions 
were 20:8 and 9.0 months, respectively (95% CL 10.4 to 
31.1 months; range 1 day to 14.5 years). POpulation data 
did not differ significantly between the blood and crystal- 
loid cardioplegia groups (Table II). Informed consent was 
obtained from parents of all patients before entry into the 
study. 
Randomization. Patients were prospectively random- 
ized to receive either blood (4:1 dilution, blood/Plegisol, 
potassium chloride adjusted to 15 mEq/L) or crystalloid 
cardioplegic solution (Plegisol). Approximately 1 hour 
before the start of the operation , the perfusionist opened 
a prepackaged envelope containing the randomized car- 
dioplegia assignment. Sixty-two patients (45%) received 
blood cardioplegia nd 76 patients (55%) received crys- 
talloid cardioplegia. Randomization was not blinded be- 
cause of the visual characteristics of the cardioplegic 
solutions. The constituents of the two cardioplegic agents 
are described in the appendix. 
Operative protocol. Cardiopulmonary b pass was insti- 
tuted at normothermia with a slightly hypocalcemic prime 
(0.75 to 1 retool/L) and with relatively normoxemic oxygen 
tensions (oxygen tension = 125 to 160 mm Hg). Systemic 
hypothermic perfusion to 30°C was achieved in all pa- 
tients, and then the aorta was crossclamped and antegrade 
cardioplegia dministered. A temperature probe was 
placed posteriorly in the interventricuiar septum, and a 
topical gauze sponge containing ice slush was placed 
anteriorly over the ventricular mass. Continued systemic 
cooling to 25 ° C was subsequently achieved in the majority 
of patients. Patients undergoing complex repairs or pa- 
tients requiring circulatory arrest periods of more than 
several minutes underwent further systemic cooling 
(range 22 ° to 16 ° C) after aortic crossclamping at 30 ° C. 
Forty patients (29%) underwent otal circulatory arrest 
(mean and median circulatory ~irrest imes 32.8 and 29.0 
minutes, respectively; 95% CL 24.7 to 48.9 minutes; range 
1 to 87 minutes). 
Cardioplegic administration was as follows: a 30 ml/kg 
dose of cardioplegic solution was initially administered 
antegradely at4 ° C with simultaneous monitoring of aortic 
root pressure. 4 Delivery of the cardioplegic solution was 
accomplished over 2 to 4 minutes, and flow was controlled 
to maintain an aortic root pressure between mean sys- 
temic arterial and diastolic pressures. Repeated oses of 
cardioplegic solution (15 ml/kg) were administered at20- 
to 30-minute intervals depending on the conduct of the 
operation and maintenance of septal temperature at15 ° C 
or less. At the completion of the aortic crossclamp eriod 
the heart was filled with blood or saline solution, or both, 
and vigorously vented for air. On removal of the aortic 
crossclamp, reperfusion was controlled by gradually in- 
creasing cardiopulmonary b pass flow to 25%, 50%, 75%, 
1004 Young et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
December 1997 
Table II. Population data for blood versus 
crystalloid cardioplegia 
Blood: Crystalloid: 
Mean Mean p 
(95% CL) (95% CL) Value 
Age (mo) 35.6 (22.2-46.9) 28.8 (19.1-38.4) 0.45* 
Aortic crossclamp 68.8 (66.7-77.0) 65.9 (58.5-73.3) 0.59* 
time (min) 
Urgent cases 7 11 0.62t 
(No. of patients) 
Cyanotic ases 30 24 
(No. of patients) 0.08? 
CL, Confidence limits. 
*Student's  test. 
tFisher's exact test. 
and 100% levels at 2- to 3-minute intervals. The calcium 
concentration f the systemic perfusate was corrected to a 
normal range approximately 15 to 20 minutes after aortic 
unclamping or just before termination of cardiopulmo- 
nary bypass. Ventricular distention during reperfusion 
and rewarming was avoided by regulation of systemic 
venous return or by ventricular sumping (or by a combi- 
nation of these methods). Dopamine (5/xg/kg per minute) 
was routinely administered before discontinuation of car- 
diopulmonary bypass. 
Clinical determinants (independent variables). The 
following determinants were analyzed as predictors of 
outcome: (1) cardioplegic solution (blood vs crystalloid), 
(2) urgency of operation (elective vs urgent), (3) aortic 
crossclamp time (minutes), (4) age of the patient 
(months), and (5) cyanosis. 
Clinical end points (dependent variables). The follow- 
ing clinical end points were evaluated: (1) ventricular 
function determined echocardiographically, (2) inotropic 
dependency, (3) complication rate, (4) length of stay in 
the intensive care unit (ICU), and (5) 30-day survival. 
Echocardiographic assessment of global and segmental 
ventricular function was performed by an echocardiologist 
and graded on a scale of i to 10 (1 = worst, 10 = best; 5 
points maximum each for global and segmental function). 
Echocardiograms were performed uring the operation 
after weaning from cardiopulmonary b pass (ECHO-OR) 
and in the first 24 hours after the operation (ECHO-PO). 
The total dose of inotropic support was calculated uring 
th e operation 30 minutes after discontinuation of cardio- 
pulmonary bypass (INT-OR) and at the end of the first 8 
hours after the operation (INT-PO). An inotropic dosage 
score based on relative inotropic potencies was calculated 
as dopamine + dobutamine + amrinone + 10 × isopro- 
terenol + 100 x epinephrine in micrograms per kilogram 
per minute. ICU length of stay was truncated at 30 days to 
minimize the influence of outliers on calculated means 
and variances. 
Statistical analysis, Standard techniques were used to 
calculate descriptive statistics. Variability was analyzed 
using confidence limits (CL). Confidence limits for nom- 
inal variables were calculated according to the normal 
approximation to the binomial distribution. Confidence 
limits for interval variables were calculated by means of 
Table I lL  Results of multiple logistic regression 
analysis for 30-day hospital mortality and 
complications 
95% CL 
P 
Independent variables Odds ratio Lower Upper Value 
Mortality 
Cardioplegia 1.543 0.524 4.538 0.431 
Aortic crossclamp time 1.068 1.027 1.111 0.001 
Age 0.962 0.901 1.028 0.256 
Urgency 0.861 0.273 2.712 0.798 
Cyanosis 1.081 0.395 2.956 0.880 
Complications 
Cardioplegia 1.008 0.678 1.497 0.970 
Aortic crossclamp time 1.026 1.012 1.041 0.0004 
Age 1.000 0.991 1.009 0.974 
Urgency 0.779 0.433 1.403 0.406 
Cyanosis 0.786 0.509 1.214 0.277 
CL, Confidence limits. 
the standard error of the mean. Full and partial correla- 
tion coefficients were used to calculate the strengths of 
association between pairs of variables. The statistical 
significance of associations between pairs of variables was 
evaluated with the use of )(2 or Fisher's exact test as 
appropriate (given number of categories and sample size) 
for nominal variables and Student's t test for interval- 
dependent variables. The statistical significance of multi- 
variate associations was evaluated by means of multiple 
logistic regression for binary-dependent variables (e.g., 
occurrence of any postoperative complication). Confi- 
dence intervals around odds ratios calculated in multiple 
logistic regressions were calculated by means of the Wald 
statistic, and multivariate analysis of covariance was used 
to explore the association Of cardioplegic agents with 
interval-dependent variables (i.e., volume of inotropic 
support, echocardiographic rating of ventricular function, 
and ICU length of stay) considered individually, while 
controlling for covariates (i.e., crossclamp time, age, pre- 
operative cyanosis, and agency of the procedure). Statis- 
tics were calculated with the use of the computer program 
SPSS for Windows, version 7.0 (SPSS, Inc., Chicago, Ill.). 
Results 
Survival and complications. By multiple logistic 
regression analysis, aortic crossclamp time (mean 
67.2 minutes; median 63.5 minutes; 95% CL 61.8 to 
72.6 minutes; range 9 to 228 minutes) was the only 
determinant that had a statistically significant asso- 
ciation with survival (p = 0.001; Table III). The 
mean aortic crossclamp time for survivors was 63.8 
minutes (5%0 to 68.6 minutes; 95% CL), compared 
with a mean crossclamp time for nonsurvivors of 
122.3 minutes (81.1 to 163.4 minutes; 95% CL). 
Among the eight nonsulvivors, three deaths oc- 
curred in patients judged to have adequate repairs 
but inadequate ventricular function (and possibly 
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Table IV. Incidence of mortafity and complications 
for cardioplegia, urgency, and cyanosis 
Mortality Complications 
No. of % of No. of % of 
patients n patients n 
Cardioplegia 
Blood 2 3.2 22 35.5 
(n = 62) 
Crystalloid 6 7.9 25 32.9 
(n = 76) 
Urgency 
Elective 6 5.0 38 31.7 
(n = 120) 
Urgent 2 11.1 9 50.0 
(n : 18) 
Cyanosis 
Noucyanotic 4 4.8 22 26.2 
(n = 84) 
Cyanotic 4 7.4 25 46.3 
(n = 54) 
*p > 0.10 (Fisher's exact est). 
"~p < 0.05 (Fisher's exact est). 
inadequate myocardial protection). Five deaths 
occurred as a result of suboptimal anatomic or 
physiologic correction. The mean age for survi- 
vors was 32.7 months (95% CL 24.7 to 40.7 
months) compared with a mean age of 9.8 months 
(95% CL 2.1 to 17.5 months) for patients who 
died. This difference in mean ages between those 
who survived and those who died was statistically 
significant in bivariate comparison (Student's t = 
4.42, df = 39.89,p, 0.001) but not in the multivar- 
iate analysis of factors associated with survival. 
Two patients (2/62 = 3.2%) receiving blood car- 
dioplegia died, and six patients (6/76 = 7.9%) who 
received crystalloid cardioplegia died (p = 0.29, 
Fisher's exact test, Table IV). Multiple logistic 
regression did not find this difference in mortality 
rate to be significant at the p < 0.05 level (p = 
0.431; Table III). Complications were likewise 
found by multiple logistic regression to have 
statistically significant associations only with aor- 
tic crossclamp time (p = 0.0004) and not with 
cardioplegia (p = 0.970; Table III). Cyanotic 
patients had a higher incidence of complications 
than did noncyanotic patients (p = 0.028, Fisher's 
exact test, Table IV). The types of complications 
were fairly typical for this spectrum of patients 
(Table V). 
Inotropic support, ventrieular function, and ICU 
length of stay. Multivariate analysis of variance 
(Table VI) for postrepair notropic support, ventric- 
Table V. Incidence of postoperative complications 
and 30-day hospital mortality for 138 patients 
Complication n % of 138 
None 91 66.0 
Pulmonary 14 10.1 
Arrhythmia 9 6.5 
Infectious 7 5.1 
Organ failure 6 4.3 
Reoperation 5 3.6 
Neurologic 3 2.2 
Tamponade 2 1.4 
Other 15 10.9 
Mortality 8 5.8 
ular function, and ICU length of stay revealed once 
again that ischemic time was the most important 
determinant and that prolonged aortic crossclamp 
time adversely influenced all measured end points. 
Younger age was associated with more inotropic 
support during the operation (p = 0.032). Patients 
requiring urgent surgery had longer ICU stays (iv = 
0.001). Cyanotic patients received more inotropic 
support after the operation (p = 0.005) but other- 
wise were not demonstrably different with respect to 
intraoperative inotropic support, echocardiographic 
findings, or ICU length of stay. 
By all statistical analyses, the use of blood cardio- 
plegia failed to have a statistically advantageous 
association with any of the clinically measured end 
points. Crystalloid cardioplegia was associated with 
less inotropic support during the operation but not 
with better ventricular function when compared 
with blood cardioplegia (Table VI). The cardiople- 
gic agent used did not have a statistically significant 
association with any of the other clinical or care 
process end points. 
Discussion 
This study was designed at a time (1994) when 
integrated blood cardioplegic techniques (i.e., ante- 
grade, retrograde, warm induction, and warm reper- 
fusion) had become associated with improved re- 
sults in adult patients, and their feasibility in 
pediatric patients had been demonstrated. 5-9 Al- 
though we used integrated blood cardioplegia for 
adults, like many others we used cold antegrade 
crystalloid cardioplegia (Plegisol solution) com- 
bined with systemic hypothermia for pediatric myo- 
cardial protection. Because of occasional experi- 
ences with a heart that functioned worse than 
expected after aortic crossclamping, as well as an 
awareness of the growing evidence of the superiority 
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Table VI. Results of multivariate analysis of variance for inotropic support, ventricular function, and ICU 
length of stay 
Determinants (independent variables) 
Cardioplegia Urgency Cyanosis 
Aortic Elective: 
Blood: Cryst: crossclamp mean Urgent." Noncyan: Cyan: 
Dependent mean mean time Age [95% mean mean mean 
variables [95% CL] [95% CL] (b) (b) CL] [95% CL] [95% CL] [95% CL] 
INT-OR 7.45 5.15§ 0.049¶ -0.019:) 5.76 9.04? 5.07 7.87* 
(/xg/kg/min) [6.0-8.9] [4.2-6.1] [5.0-6.5] [5.1-13.0] [4.1-6.0] [6.4-9.4] 
INT-PO 6.16 5.14" 0.050¶ -0.009* 5.11 8.80* 4.01 7.99§ 
(tzg/kg/min) [4.8-7.5] [4.0-6.3] [4.2-6.0] [5.8-11.8] [3.0-5.0] [6.6-9.4] 
ECHO-OR 9.45 9.55* -0.009§ 0.001" 9.56 9.17" 9.64 9.30* 
grade 1-10 [9.1-9.8] [9.3-9.8] [9.4-9.8] [8.5-9.8] [9.4-9.9] [9.0-9.6] 
ECHO-PO 9.52 9.22* -0.023¶ 0.005? 9.38 9.22* 9.43 9.25* 
grade 1-10 [9.3-9.8] [8.8-9.6] [9.1-9.7] [8.6-9.9] [9.1-9.8] [8.9-9.6] 
ICU days 7.65 7.55* 0.080¶ -0.009* 6.53 14.72¶ 5.64 10.557 
[5.7-9.6] [5.9-9.2] [5.4-7.7] [10.1-19.3] [4.4-6.8] [8.2-12.9] 
Mean, Mean value for each dependent variable (e.g., INT-OR) within subgroups defined by determinants (e.g., blood cardioplegia), b slope by regression 
analysis; CL, confidence limits; Cryst, crystalloid; Cyan, cyanotic; ECHO, echocardiographic assessment ofventficular function intraoperatively (OR) and 
postoperatively (PO); INT, total dose of inotropic support intraoperatively and postoperatively. Exact p values are presented in the text. p values were 
obtained from multivariate analysis of variance for each dependent variable considered individually. Across cardioplegia groups, patients received agrand 
mean of 6.9/xg/kg/min (95% CL 5.34 to 7.03) intraoperative inotropic support; a grand mean of 6.0/~g/kg/min (95% CL 4.74 to 6.46) of inotropic support 
in the first 8 hours postoperatively. The grand mean grading of intraoperative ventricular function was 9.51 (95% CL 9.32 to 9.70), and at 24 hours 
postoperatively was 9.36 (95% CL 9.11 to 9.61). The grand mean ICU length of stay was 7.59 days (95% CL 6.37 to 8.82). 
*p > 0.10. 
?p > 0.05. 
~p < 0.05. 
§p < 0.01. 
¶p < 0.001. 
of integrated blood cardioplegic techniques in 
stressed hearts, we felt compelled to evaluate the 
clinical use of blood cardioplegia for our pediatric 
patients, m The technical disadvantages of using 
retrograde and warm blood cardioplegia techniques 
in some pediatric patients, particularly newborn 
infants, prompted us to use blood essentially as an 
additive to our cardioplegic strategy, thus random- 
izing patients to either Plegisol solution or blood 
with Plegisol solution. Because some investigators 
raised questions regarding the optimum systemic 
perfusate temperature atwhich aortic crossclamping 
should occur, we chose a moderately hypothermic 
temperature for aortic crossclamping (30 ° C). 11-13 
This type of study has important limitations. The 
differences in myocardial cellular and subcellular 
functions in neonates, the effects of cyanosis, car- 
diopulmonary bypass, systemic perfusion tempera- 
tures, and of reperfusion, and the varied pathologic 
entities involved obfuscate cardioplegic effects. 14-18 
Arbitrary decision-making for inotropic support and 
subjective chocardiographic assessment of ventric- 
ular function lessen the validity of the conclusions 
from these portions of the study. Technical and 
physiologic hallenges are common in complex con- 
genital heart surgery, and prolonged ischemia or 
suboptimal physiologic results may overshadow the 
benefits or differences of cardioplegic agents. Last, 
arguments abound regarding the benefits of various 
ion concentrations, for example, calcium, in car- 
dioplegic solutions, and a clinical study of this size 
cannot possibly adequately address all of these 
issues. 19-22 
Our study failed to show any statistical advantage 
for blood cardioplegia, but these results are not 
surprising inasmuch as good results have been re- 
ported with either cold blood or cold crystalloid 
antegrade cardioplegic techniques in the pediatric 
age group. 9° 23, 24 In fact, in our study the postoper- 
ative ventricular function as measured by echocar- 
diographic mean score was quite good for both the 
blood and crystalloid cardioplegia groups, that is, 
ECHO-PO 9.52 for blood cardioplegia nd 9.22 for 
crystalloid cardioplegia (scale 1 to 10; Table VI). 
Our study failed to demonstrate any benefit of blood 
cardioplegia in cyanotic patients. Despite the equiv- 
ocal findings of our study, limitations of antegrade 
cold crystalloid cardioplegia have been previously 
noted,25, 26 and the increasing evidence of the ben- 
efits of integrated blood cardioplegia, as well as 
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recent experimental evidence suggesting the superi- 
ority of blood cardioplegia for cyanotic patients, 
provide compelling reasons for adopting a blood 
cardioplegic strategy. I7. 
Perhaps the most important aspect of this study is 
the recognition that no obvious benefits, if any, can 
be anticipated by use of a blood cardioplegic strat- 
egy in surgery for congenital heart disease when only 
an antegrade hypothermic dosing technique is used. 
The integrated cardioplegic approach using warm, 
cold, antegrade, and retrograde techniques with 
substrate nhancement has achieved well-deserved 
popularity in adults and may be beneficial for the 
pediatric population as well. It is unclear whether 
this approach is safe in all pediatric patients, partic- 
ularly neonates, but the technical feasibility of an 
integrated approach in neonates has been demon- 
strated. 27 It is important o note, however, that the 
efficacy of integrated cardioplegic techniques has 
not been demonstrated clinically in neonates or 
young infants. 
Because of its demonstrated superiority in adults 
and infant animal studies, we currently attempt o 
use an integrated blood cardioplegic regimen in as 
many pediatric patients as possible, for example, 
using antegrade cold blood cardioplegia for opera- 
tions in neonates and younger infants with warm 
cardioplegic reperfusion at the end of the ischemic 
period and before aortic unclamping. In older chil- 
dren, it is easy to use a fully integrated system 
incorporating warm substrate-enriched antegrade 
and retrograde techniques at the initiation and 
conclusion of the ischemic period with intermittent 
cold blood cardioplegia during the remainder of the 
ischemic arrest. Crystalloid cardioplegia is currently 
reserved for patients with anticipated brief ischemic 
times and in whom the use of blood cardioplegia 
might require addition of blood to the priming 
circuit (e.g., atrial septal defects in the older child). 
Further elucidation of myocyte ion fluxes, sub- 
cellular apparatus mechanisms, and coronary en- 
dothelial processes will undoubtedly improve our 
understanding and alter our myocardial protective 
strategies for both pediatric and adult populations. 
The potential benefits that may be derived from 
various substrate enhancements, preconditioning 
*Bolling K, Allen B, Rahman S, Wang T, Kronon M, Feinberg H. 
The superiority of blood versus crystalloid cardioplegia in 
neonatal myocardial protection. Presented at the Twenty- 
second Annual Meeting of The Western Thoracic Surgical 
Association, June 26-29, 1996. 
agents, or hyperpolarizing substances remain to be 
demonstrated.28, 9 Because of the major effect of 
aortic crossclamp time (ischemic time) on clinical 
results, we must continue to look to experimental 
animal models and investigations to help clarify 
these issues. 
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Discussion 
Dr. Bradley S. Allen (Chicago, ILL). Although numerous 
investigators have demonstrated the superiority of blood 
over crystalloid cardioplegia n the mature heart, few have 
examined this question in the immature heart. In view of 
the structural, functional, and metabolic differences, ex- 
trapolation of adult cardioplegic strategies to the infant 
may not be valid. This study seems to demonstrate no 
difference between blood and crystalloid cardioplegia. 
However, unlike experimental studies in which the preop- 
erative state and operative procedure are identical, these 
variables are often very different between patients, making 
the data ditficult o interpret. 
I have several questions for the authors. The composi- 
tion of Plegisol solution is based on numerous studies that 
determined the optimal evel for each component when 
used as a crystalloid solution. Likewise, the ideal compo- 
sition of blood cardioplegia was determined by a similar 
process. In other words, blood cardioplegia is more than 
just adding blood to Plegisol solution, because the result- 
ing solution has not been specifically formulated to opti- 
mize myocardial protection. Do the authors believe that 
this could have affected their results, and do they have any 
experience with some of the more conventional b ood 
cardioplegic solutions? 
Second, inasmuch as the pediatric heart may be more 
tolerant o ischemia, it is not surprising that there is no 
difference between blood and crystalloid cardioplegia in 
normal hearts with relatively short crossclamp times. 
Although the authors excluded simple atrial septal defects 
for this reason, 50% of their patients had ventricular 
septal defects or uncomplicated aortic stenosis. These 
children should do well no matter what the method of 
myocardial protection. Therefore, was there a difference 
between blood and crystalloid cardioplegia in patients 
undergoing more complex procedures requiring longer 
crossclamp times, especially since crossclamp time was a 
predictor of a bad outcome? 
The morbidity and mortality in cyanotic infants were 
increased, supporting other reports which document that 
these infants are less tolerant o ischemia nd therefore 
more dependent on the method of myocardial protection. 
In a recent experimental study, we demonstrated that in 
hypoxic hearts blood cardioplegia provides ubstantially 
better myocardial protection than does crystalloid cardio- 
plegia. Do the authors know whether there was any 
difference between blood and crystalloid cardioplegia 
when only the cyanotic patients were compared? 
We recently found that myocardial protection is mark- 
edly improved in neonatal hearts when the cardioplegic 
solution is delivered at a pressure less than 50 mm Hg. 
Inasmuch as you measured the cardioplegic infusion 
pressure, could you tell us what it was in each group and 
whether it differed between groups? 
Finally, the two cardioplegic solutions were delivered 
according to identical protocols. Although using similar 
delivery strategies reduces variability in the study, it does 
not allow each solution to be used to its maximal poten- 
tial. For instance, using a warm reperfusion or "hot shot" 
before aortic unclamping has previously been shown to 
improve myocardial protection with blood cardioplegia n
adults. We have recently demonstrated this to be true as 
well in neonates. Since a warm reperfusate would proba- 
bly be deleterious if delivered via a crystalloid solution, it 
is never used when identical protocols are followed. 
However, if this modality is not incorporated, blood 
cardioplegia is not used to its maximal potential. There- 
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fore the question of which solution is better cannot be 
determined. Since the authors tate that they now use a 
warm reperfusate in most pediatric patients, could they 
comment on whether they think incorporating this strat- 
egy would have changed their results? 
This is an important paper. Only from studies uch as 
this will we be able to determine the optimal method of 
protection in infants, instead of adopting strategies deter- 
mined in the adult. 
Dr. Young. Dr. Allen, thank you for your comments and 
questions. You asked five questions, and I will combine 
my answers. 
The first and the fifth questions concerned the compo- 
nents of the cardioplegic agent and the different ech- 
niques. We designed this study in 1994 when we were 
routinely using antegrade blood cardioplegic techniques 
in our adult patients but using just cold crystalloid cardio- 
plegia in our pediatric patients. I was reluctant to move 
too far too fast, because we thought hat the results with 
the crystalloid solution were good. Additionally, the tech- 
nical issues of using a retrograde technique in newborn 
infants can be problematic; therefore we elected to use 
only antegrade cold agents. We have had some experience 
now, as I know you have, with retrograde techniques in 
older children. We do not use them very much yet in 
newborn infants, but certainly in older children it is fairly 
easy to use an antegrade blood cardioplegic technique 
with warm induction, cold maintenance, hot shot, and 
substrate r perfusions. However, I do not have any data to 
report to you from that experience. 
I agree that it is an oversimplification to suggest hat 
adding blood to Plegisol solution creates an additive 
situation. Obviously this is a topic for a long discussion 
concerning which agents hould be used. I know you and 
your group have done extensive work in this area. How- 
ever, we were using Plegisol solution plus blood in our 
adult population; we were halSpy with those results, and 
we thought that was a logical first step, because there were 
no large differences between the two agents. 
We found no difference at all among the cyanotic 
patients between the two cardioplegia groups. We mea- 
sure pressures routinely in the aortic root when adminis- 
tering cardioplegia. I think it is important o do so, 
particularly in the younger infant and smaller child, 
because damage can occur if pressure is not accurately 
measured, as has been demonstrated by several studies. 
However, we did not address pressure differences per se 
as one of the determinants in this population. 
Appendix. Constituents of Plegisol solution and 
blood cardioplegic solution 
Plegisol Blood cardioplegia 
Na + 120 mEq/L 
K + 16 mEq/L 
Mg ++ 32 mEq/L 
Ca ++ 2.4 mEq/L 
HCO 3- 10 mEq/L 
C1 160 mEq/L 
pH 7.8 mEq/L 
Blood/Plegisol = 4:1 
K + = 15 mEq/L 
